Avesthagen Limited launches AVGEN Diagnostics, an integrated personalised genetic testing service

Mumbai: Avesthagen Limited launched AVGEN Diagnostics an integrated end-to-end personalised genetic testing service. The platform employs the latest in NGS sequencing technology and AI driven precision analytics that drive diagnostic testing services at B2C, B2B levels forging partnerships with hospitals, private clinics and health insurers. The portfolio includes tests for common diseases, customised panels for different disease conditions and comprehensive disease risk panels, interpreting all genes associated with the patient’s phenotype.

The portfolio addresses cancers, cardiac care diagnostics, neurodegenerative conditions, autoimmune conditions, rare diseases, pharmacogenomics, ancestry analysis and a unique set of tests for women’s health-reproductive genomics and fertility testing, carrier screening, and pre-natal diagnostics with precision analytics powered by Congenica, UK a digital health company, that enables precision medicine through its AI-powered diagnostic decision support platform for genomic data. AVGEN Diagnostics will be uniquely supported by the R&D outcomes of its flagship, The Avestagenome Project, which will provide accelerated and continuous innovation to create a pipeline of novel diagnostic tests, enabling best-in-class patient care. The portfolio offers a thorough and cost-effective diagnostic tool for individuals with distinctive clinical features and rapid interpretation of next-generation sequencing data with confidence, improving patient outcomes, and reducing the burden on healthcare systems.

Dr Villoo Morawala Patell, Chairperson and Managing Director, Avesthagen and The Avestagenome Project, said, “Our genetic testing service aims to consolidate all the critical genetic biomarkers into a single, effective, and comprehensive testing platform that de-risk individual health by identifying clinical variants especially in those with genetic predisposition to heritable disorders that would otherwise require time-consuming sequential gene tests. Our partnership with Congenica enables us to accelerate preventive and early diagnosis to deliver personalised medicine across India.”